Epigallocatechin gallate decreases plasma triglyceride, blood pressure, and serum kisspeptin in obese human subjects

• Published in: Experimental biology and medicine (Maywood, N.J.) Vol. 246; no. 2; pp. 163 - 176
• Main Authors: Chatree, Saimai, Sitticharoon, Chantacha, Maikaew, Pailin, Pongwattanapakin, Kitchaya, Keadkraichaiwat, Issarawan, Churintaraphan, Malika, Sripong, Chanakarn, Sririwichitchai, Rungnapa, Tapechum, Sompol
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2021
• Subjects: Adipocytes, Brown - drug effects; Adipocytes, Brown - metabolism; Adipocytes, White - drug effects; Adipocytes, White - metabolism; Adiponectin - blood; Adult; Blood Glucose - metabolism; Blood Pressure - drug effects; Catechin - analogs & derivatives; Catechin - pharmacology; Humans; Kidney - drug effects; Kidney - physiopathology; Kisspeptins - blood; Leptin - blood; Lipolysis; Liver - drug effects; Liver - physiopathology; Middle Aged; Obesity - blood; Obesity - genetics; Obesity - physiopathology; Original Research; RNA, Messenger - genetics; RNA, Messenger - metabolism; Triglycerides - blood; Uncoupling Protein 1 - genetics; Uncoupling Protein 1 - metabolism; Obesity; blood pressure; human adipocytes; epigallocatechin gallate; plasma triglyceride; kisspeptin
• ISSN: 1535-3702; 1535-3699; 1535-3699
• DOI: 10.1177/1535370220962708

Obesity is one of major risk factors increasing chronic diseases including type II diabetes, cardiovascular diseases, and hypertension. The effects of epigallocatechin gallate (EGCG), the major active compound in green tea, on reduced obesity and improved metabolic profiles are still controversial. Furthermore, the effects of EGCG on human adipocyte lipolysis and browning of white adipocytes have not been elucidated. This study aimed to investigate the effects of EGCG on obesity, lipolysis, and browning of human white adipocytes. The results showed that, when compared to the baseline values, EGCG significantly decreased fasting plasma triglyceride levels (P < 0.05), systolic blood pressure (P < 0.05), diastolic blood pressure (P < 0.05), and serum kisspeptin levels (P < 0.05) after 8 weeks of supplement. On the other hand, supplement of EGCG in obese human subjects for 4 or 8 weeks did not decrease body weight, body mass index, waist and hip circumferences, nor total body fat mass or percentage when compared to their baseline values. The study in human adipocytes showed that EGCG did not increase the glycerol release when compared to vehicle, suggesting that it had no lipolytic effect. Furthermore, treatment of EGCG did not enhance uncoupling protein 1 (UCP1) mRNA expression in human white adipocytes when compared with treatment of pioglitazone, the peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, suggesting that EGCG did not augment the browning effect of PPAR-γ on white adipocytes. This study revealed that EGCG reduced 2 metabolic risk factors which are triglyceride and blood pressure in the human experiment. We also showed a novel evidence that EGCG decreased kisspeptin levels. However, EGCG had no effects on obesity reduction in humans, lipolysis, nor browning of human white adipocytes.